FRANCOIS MELLOT

Dr. FRANCOIS MELLOT

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
SCShikha Chaganti
Shikha Chaganti
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier
ABAbishek Balachandran
Abishek Balachandran
GCGuillaume Chabin
Guillaume Chabin
SCStuart Cohen
Stuart Cohen
DCDorin Comaniciu
Dorin Comaniciu
Purpose To present a method that automatically segments and quantifies abnormal CT patterns commonly present in coronavirus disease 2019 (COVID-19), namely ground glass opacities and consolidations...

8 October 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier
ABAnne-Laure Brun
Anne-Laure Brun
FMFRANCOIS MELLOT
FRANCOIS MELLOT
Two large randomized controlled trials of low-dose CT (LDCT)-based lung cancer screening (LCS) in high-risk smoker populations have shown a reduction in the number of lung cancer deaths in the screening group compared to a control group. Even if various countries are currently considering the implementation of LCS programs, recurring doubts and fears persist about the potentially high false positive rates, cost-effectiveness, and the availability of radiologists for scan interpretation. Artificial intelligence (AI) can potentially increase the efficiency of LCS. The objective of this article is to review the performances of AI algorithms developed for different tasks that make up the interpretation of LCS CT scans, and to estimate how these AI algorithms may be used as a second reader. Despite the reduction in lung cancer mortality due to LCS with LDCT, many smokers die of comorbid smoking-related diseases. The identification of CT features associated with these comorbidities could increase the value of screening with minimal impact on LCS programs. Because these smoking-related conditions are not systematically assessed in current LCS programs, AI can identify individuals with evidence of previously undiagnosed cardiovascular disease, emphysema or osteoporosis and offer an opportunity for treatment and prevention.

30 April 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ABAnne-Laure Brun
Anne-Laure Brun
MCMarie-Laure Chabi
Marie-Laure Chabi
CPClément Picard
Clément Picard
FMFRANCOIS MELLOT
FRANCOIS MELLOT
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier
Chronic lung allograft rejection remains one of the major causes of morbi-mortality after lung transplantation. The term Chronic Lung Allograft Dysfunction (CLAD) has been proposed to describe the different processes that lead to a significant and persistent deterioration in lung function without identifiable causes. The two main phenotypes of CLAD are Bronchiolitis Obliterans Syndrome (BOS) and Restrictive Allograft Syndrome (RAS), each of them characterized by particular functional and imaging features. These entities can be associated (mixed phenotype) or switched from one to the other. If CLAD remains a clinical diagnosis based on spirometry, computed tomography (CT) scan plays an important role in the diagnosis and follow-up of CLAD patients, to exclude identifiable causes of functional decline when CLAD is first suspected, to detect early abnormalities that can precede the diagnosis of CLAD (particularly RAS), to differentiate between the obstructive and restrictive phenotypes, and to detect exacerbations and evolution from one phenotype to the other. Recognition of early signs of rejection is crucial for better understanding of physiopathologic pathways and optimal management of patients.

2 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
VGVictor Gravrand
Victor Gravrand
FMFRANCOIS MELLOT
FRANCOIS MELLOT
FAFelix Ackermann
Felix Ackermann
MBMarie-Christine Ballester
Marie-Christine Ballester
BZBenjamin Zuber
Benjamin Zuber
Marc VasseMarc Vasse
Marc Vasse
SeptiCyte® RAPID is a gene expression assay measuring the relative expression levels of host response genes PLA2G7 and PLAC8, indicative of a dysregulated immune response during sepsis. As severe forms of COVID-19 may be considered viral sepsis, we evaluated SeptiCyte RAPID in a series of 94 patients admitted to Foch Hospital (Suresnes, France) with proven SARS-CoV-2 infection. EDTA blood was collected in the emergency department (ED) in 67 cases, in the intensive care unit (ICU) in 23 cases and in conventional units in 4 cases. SeptiScore (0–15 scale) increased with COVID-19 severity. Patients in ICU had the highest SeptiScores, producing values comparable to 8 patients with culture-confirmed bacterial sepsis. Receiver operating characteristic (ROC) curve analysis had an area under the curve (AUC) of 0.81 for discriminating patients requiring ICU admission from patients who were immediately discharged or from patients requiring hospitalization in conventional units. SeptiScores increased with the extent of the lung injury. For 68 patients, a chest computed tomography (CT) scan was performed within 24 h of COVID-19 diagnosis. SeptiScore >7 suggested lung injury ≥50% (AUC = 0.86). SeptiCyte RAPID was compared to other biomarkers for discriminating Critical + Severe COVID-19 in ICU, versus Moderate + Mild COVID-19 not in ICU. The mean AUC for SeptiCyte RAPID was superior to that of any individual biomarker or combination thereof. In contrast to C-reactive protein (CRP), correlation of SeptiScore with lung injury was not impacted by treatment with anti-inflammatory agents. SeptiCyte RAPID can be a useful tool to identify patients with severe forms of COVID-19 in ED, as well as during follow-up.

14 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MCMarie-Laure Chabi
Marie-Laure Chabi
ODOphelie Dana
Ophelie Dana
TKTitouan Kennel
Titouan Kennel
AGAlexia Gence-Breney
Alexia Gence-Breney
HSHélène Salvator
Hélène Salvator
Philippe A. GrenierPhilippe A. Grenier
Philippe A. Grenier
The purpose of our work was to assess the independent and incremental value of AI-derived quantitative determination of lung lesions extent on initial CT scan for the prediction of clinical deterioration or death in patients hospitalized with COVID-19 pneumonia. 323 consecutive patients (mean age 65 ± 15 years, 192 men), with laboratory-confirmed COVID-19 and an abnormal chest CT scan, were admitted to the hospital between March and December 2020. The extent of consolidation and all lung opacities were quantified on an initial CT scan using a 3D automatic AI-based software. The outcome was known for all these patients. 85 (26.3%) patients died or experienced clinical deterioration, defined as intensive care unit admission. In multivariate regression based on clinical, biological and CT parameters, the extent of all opacities, and extent of consolidation were independent predictors of adverse outcomes, as were diabetes, heart disease, C-reactive protein, and neutrophils/lymphocytes ratio. The association of CT-derived measures with clinical and biological parameters significantly improved the risk prediction (p = 0.049). Automated quantification of lung disease at CT in COVID-19 pneumonia is useful to predict clinical deterioration or in-hospital death. Its combination with clinical and biological data improves risk prediction.

19 July 2021 in Japanese Journal of Radiology
Verified
Journal Article
Closed access
PDF file
GGGuillaume Gravel
Guillaume Gravel
ARAlexandre Roussel
Alexandre Roussel
FMFRANCOIS MELLOT
FRANCOIS MELLOT